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AbstrACt
Introduction Chronic pancreatitis (CP) is thought to 
present the end stage of a continuous disease process 
evolving from acute pancreatitis (AP), over recurrent AP, 
to early and end-stage CP. Due to the irreversible nature 
of CP, early detection and prevention is key. Prospective 
assessment based on advanced imaging modalities as 
well as biochemical markers of inflammation, fibrosis and 
oxidative stress may provide a better understanding of 
the underlying pathological processes and help identify 
novel biomarkers of disease with the ultimate goal of 
early diagnosis, intervention and prevention of disease 
progression. This paper describes the protocol of a 
prospective multicentre cohort study investigating the 
fibroinflammatory process involved in progression from 
acute to CP using state-of-the-art diagnostic imaging 
modalities and circulating biomarkers of inflammation, 
fibrosis and oxidative stress.
Methods and analysis Adult control subjects and 
patients at different stages of CP according to the 
M-ANNHEIM system will be recruited from outpatient 
clinics at the participating sites and form three cohorts: 
controls (n=40), suspected CP (n=60) and definitive CP 
(n=60). Included patients will be followed prospectively 
for 15 years with advanced MRI and contrast-enhanced 
endoscopic ultrasound with elastography, assessment of 
endocrine and exocrine pancreatic function, biochemical 
and nutritional assessment, and evaluation of pain 
processing using quantitative sensory testing. Blood 
samples for a biobank will be obtained. The purpose of 
the biobank is to allow analyses of potential circulating 
biomarkers of disease progression, including markers of 
inflammation, fibrosis and oxidative stress.
Ethics and dissemination Permissions from the 
Regional Science Ethics committee and the Regional Data 
Protection Agency have been obtained. We will submit 
the results of the study for publication in peer-reviewed 
journals regardless of whether the results are positive, 
negative or inconclusive.
IntroduCtIon
Chronic pancreatitis (CP) is a progressive 
fibroinflammatory disease associated with 
persistent pathological response to paren-
chymal injury or stress.1 Over time, the 
fibroinflammatory process can lead to irre-
versible fibrosis with morphological changes 
and loss of pancreatic function. Due to the 
irreversible nature of end-stage pancreatitis, 
early detection and prevention is key.
The global pooled incidence of CP is 10 per 
100 000 general population per year2 and the 
prevalence rates are reported to be between 40 
and 50 per 100 000 persons.3 However, cumu-
lating evidence suggests that the incidence of 
CP is rising4 5 and a Danish nationwide popu-
lation-based cohort study showed a fivefold 
increased mortality rate with a life expectancy 
that was approximately 8 years less among 
patients with CP compared with population 
strengths and limitations of this study
 ► The prospective and repetitive assessment of imag-
ing, functional and biochemical parameters in the 
present study may provide clinical useful biomark-
ers for the identification of patients at increased risk 
of developing chronic pancreatitis.
 ► The relatively homogeneous population, both ge-
netically, socially and economically provide us with 
a unique and unbiased framework for studying the 
natural course of pancreatitis.
 ► A limitation of the study is that ‘state-of-the art’ im-
aging, functional, endoscopic and biochemical as-
sessment parameters may change during the study 
period, thus making comparisons over time difficult 
and potentially based on outdated technology.
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Figure 1 A large proportion of patients develop CP after 
an episode of acute pancreatitis. The development of CP 
is associated with continued or recurrent inflammation and 
progressive development of fibrosis. CP, chronic pancreatitis.
controls.6 Taken together, this illustrates that the great 
impact CP has on health, economic and social aspects.
Alcohol and smoking are the major aetiological risk 
factors of CP,7 and there seems to be an additive effect 
of alcohol and smoking. Other causes include hypercal-
caemia, hyperlipidaemia, obstruction of the biliary or 
pancreatic duct, autoimmune conditions and hereditary 
conditions. About 20% of cases are idiopathic, but this 
number is likely to decrease as the understanding of the 
pathophysiology underlying CP evolves.
Currently, the diagnosis of CP is based on a combina-
tion of symptoms, biochemical tests and imaging param-
eters. Abdominal pain is the cardinal symptom of CP and 
present in the majority of patients during their disease 
course, but the intensity and temporal pattern varies 
substantially. At later disease stages, patients may develop 
diabetes, steatorrhoea and weight loss, but the disease 
course is unpredictable in the majority of patients, thus 
making symptom-based assessment unreliable. The 
biochemical tests used for assessment of CP include 
glycated haemoglobin (HbA1c) (endocrine pancreatic 
function) and faecal elastase (FE), breath test or direct 
pancreatic function tests (exocrine pancreatic function 
tests). Diagnostic imaging is used for characterisation of 
typical morphological changes including parenchymal 
lobulation, calcifications, parenchymal atrophy, pseudo-
cysts and pancreatic duct abnormalities. Various imaging 
modalities are used for assessment including CT, MRI and 
endoscopic ultrasound (EUS).8
Some patients are diagnosed with CP without preceding 
attacks of acute pancreatitis (AP). These patients typically 
present with symptoms of end-stage disease including 
steatorrhoea, diabetes and chronic abdominal pain. 
However, a large proportion of patients diagnosed with 
CP have a history of AP or recurrent AP (RAP) (figure 1). 
In keeping with this, a meta-analysis found that 10%of 
patients with a first episode of AP and 36% of patients with 
RAP develop CP, with a higher risk of disease progression 
among smokers, alcoholics and men.2 3 9 These findings 
attest to the understanding of CP as a continuous disease 
process evolving from AP, over RAP, to early and end-stage 
CP as also outlined in a recent international consensus 
draft on a mechanistic definition of CP.1 Importantly, 
this understanding provides a theoretical framework for 
studying the fibroinflammatory processes involved in the 
development of CP by prospectively assessing patients 
admitted with AP and RAP during their course of disease 
towards early and end-stage CP. Hence, prospective 
assessment based on state-of-the-art imaging modalities as 
well as biochemical markers of inflammation, fibrosis and 
oxidative stress may provide a better understanding of the 
underlying pathological processes and help identifying 
novel biomarkers of disease with the ultimate goal of early 
diagnosis, intervention and prevention of progression. 
Along these lines, a holistic framework for prevention of 
pancreatitis has recently been introduced and outlined 
preventive measures at both primary, secondary and 
tertiary levels based on current knowledge on the natural 
course of disease progression.3
CurrEnt stAndArds And ChAllEngEs In AssEssMEnt of 
pAnCrEAtItIs
Imaging
Various imaging techniques can be used to characterise 
pancreatic morphology. CT is in most cases used for 
the initial workup and is particularly useful for detec-
tion of advanced disease characteristics of CP including 
parenchymal and intraductal calcifications, gross duct 
pathology and parenchymal atrophy.10 Furthermore, 
CT is key in ruling out relevant differential diagnosis 
including pancreatic cancer. Despite CT being the 
imaging modality of choice for initial investigation, it 
cannot exclude a diagnosis of CP, nor can it be used to 
exclusively diagnose ‘early CP’.
MRI-based techniques, including MR cholangiopan-
creatography, are more accurate for detection of pancre-
atic duct abnormalities (dilatations and strictures) and 
subtle changes of the pancreatic parenchyma and side 
branches, which can be attributed to early signs of CP.11 
The MR-based techniques can be further refined by assess-
ment of pancreatic gland volume and administration of 
secretin whereby a combined quantitative morpholog-
ical and functional assessment of the pancreatic gland 
can be obtained. This includes characterisation of subtle 
ductal abnormalities and pancreatic secretion. In addi-
tion, diffusion weighted imaging can provide a proxy of 
fibrotic changes and emerging methods like the DIXON 
technique can be used to assess fat signal fraction for eval-
uation of fatty infiltration of the pancreatic parenchyma.
The gold standard for establishing a diagnosis of early 
CP imaging is currently EUS. Diagnostic criteria related 
to the parenchyma and the pancreatic duct have been 
established, and in 2009, a weighted scoring system was 
proposed by a panel of experts, the Rosemont score.12 
Emerging endoscopic methods with assessment of 
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pancreatic blood flow and tissue stiffness by elastography 
may further improve the diagnostic utility of EUS.13
Taken together, a multimodal approach combining 
advanced MRI and EUS techniques will likely provide 
novel and complementary information on pancreatic 
morphology and function that may reflect unique aspects 
of the pathology underlying progressive pancreatitis 
disorders (AP → RAP → CP) that have not previously 
been identified using conventional imaging modalities.
Circulating biomarkers of inflammation, fibrosis and oxidative 
stress
Most of our knowledge about physiological and patho-
physiological mechanisms in healthy and diseased 
pancreas comes from experimental studies. Due to the 
anatomy, complexity and risk associated with direct 
sampling from pancreatic tissue, most of our information 
on human pancreas arises from circulating marker of 
pancreatic physiology or injury.
Inflammation
The inflammatory profile characterising early stages of 
pancreatitis may reflect the trajectory of disease and subse-
quent development of fibrosis. Hence, patients with CP 
have increased serum levels of interleukin (IL)−6, IL-4 
and IL-18,14–16 which are implicated in the wound healing 
response and the progression of fibrotic disease. Also, 
tumour necrosis factor-α may be implicated in disease 
progression.17
Fibrosis
Patients with CP have elevated plasma levels of fibrogen-
esis markers such as transforming growth factor beta-1 
(TGF-β1), soluble fractalkine and monocyte chemoat-
tractant protein-1 (MCP-1).18–20 Decreasing MCP-1 and 
TGF-β1 levels with anti-inflammatory drugs was shown 
to reduce the severity of CP in a caerulein-induced CP 
mouse model.21 Matrix metalloproteinases (MMPs) 
are a group of enzymes involved in the degradation of 
collagen, proteoglycans, elastin and fibronectin, all of 
which play an important role in the remodelling of the 
extracellular matrix. The role of MMPs in the develop-
ment of progressive fibrosis and cirrhosis is well estab-
lished22 and emerging evidence suggests that MMPs may 
have a similar role in CP.23 Elevated serum MMP-9 levels 
have been found in patients with both AP and CP, and 
active form of MMP-9 could be involved in the develop-
ment of diabetes mellitus associated with CP.24 
Oxidative stress is a result of imbalance between reactive 
oxygen species and their neutralising mechanisms, which 
may result in cell or tissue damage. Increased oxidative 
stress with the resulting formation of free radicals has 
been implicated in the pathophysiology of CP25 and treat-
ment with antioxidants has been shown to reduce disease 
and pain severity in randomised controlled trials,26 27 
although the effects may be related to the underlying aeti-
ology.28 29 Recent studies have shown that oxidative stress 
may also be implicated in RAP.30 Free radicals do not 
only exert local effect in pancreas but are also released in 
systemic circulation and can thus be quantified.
pain processing and quantitative sensory testing
The processing of pain in central pain pathways under-
goes changes in a large proportion of patients with painful 
CP. These include sensitisation of central pain pathways, 
impaired capacity of pain modulation as well as structural 
and functional changes in the brain.31 Although the pres-
ence of these changes is well documented in numerous 
cross-sectional studies, the temporal aspects of changes 
in pain processing during disease progression have not 
previously been investigated in the context of pancre-
atitis. Quantitative sensory testing (QST) can be used 
to map the pain system; the technique is based on the 
rationale that different neural pathways and networks 
can be explored using standardised stimulation with 
simultaneous recording of the evoked pain response 
by psychophysical and/or objective methods.32 Due to 
spinal convergence between visceral afferents from the 
pancreas and somatic afferents from upper abdominal 
skin dermatomes, somatic QST can be used to assess if 
the pain system is sensitised by nociceptive input from 
the pancreas.33 Together with specific test paradigms 
(temporal summation and assessment of pain modula-
tion), QST can be used to characterise the state of the 
pain system and to document if patients have abnormal 
central pain processing.
nutrition
The risk factors associated with underweight and 
malnutrition in patients with CP are complex and 
likely multifactorial with the most frequently reported 
being pancreatic exocrine insufficiency. However, many 
patients lose weight early in their disease course and 
before evolution of pancreatic exocrine insufficiency. 
For example, postprandial pain, which is seen in many 
patients, may also limit food intake and lead to under-
weight and malnutrition. There is a paucity of data on 
this important topic, and continuous characterisation of 
nutritional status in patients going through phases of AP, 
to RAP to CP may provide us with essential knowledge on 
metabolic processes related to inflammation and fibrosis. 
A combined use of bioelectrical impedance, hand grip 
strength (HGS), timed up-and-go test (TUG), assessment 
of endocrine (HbA1c) and exocrine insufficiency (FE), 
and biochemical tests enables qualitative and quantitative 
assessment of nutritional status.
hypotheses
Current knowledge on the progression of CP is mostly 
based on cross-sectional studies including patients with 
different stages of RAP and CP. By prospectively following 
well-characterised cohorts of patients with pancreatitis at 
different stages (AP → RAP → CP) with serial imaging 
(advanced MRI and EUS), profiling of fibroinflammatory 
pathways using circulating biomarkers and assessment 
of nutritional status and pain processing using QST, this 
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study will help elucidate the underlying pathophysiology 
of pancreatitis.
The hypotheses of this study are:
 ► Prospective assessment of patients progressing from 
AP to CP, using advanced imaging techniques and 
circulating biomarkers of inflammation, fibrosis and 
oxidative stress, can provide new mechanistic insight 
to the underlying fibroinflammatory process. This 
knowledge may be used to design the future clinical 
studies focusing on prevention of inflammation and 
fibrosis in the pancreas and other organ systems.
 ► Changes in pain processing over time are poorly 
understood in patients progressing from AP to CP. 
This information may be used to identify patients at 
risk for developing a chronic pain syndrome with irre-
versible neuroplastic changes in the central nervous 
system.
 ► Changes in nutritional state over time are poorly 
understood in patients progressing from AP to CP. 
This information may be used to identify patients at 
risk for developing malnutrition.
Aims
Primary aim
To prospectively investigate the fibroinflammatory process 
involved in progression from acute to CP using state-of-
the-art diagnostic imaging modalities (contrast-enhanced 
EUS, EUS-guided elastography and advanced MRI) and 
circulating biomarkers of inflammation, fibrosis and 
oxidative stress.
Secondary aim
To prospectively characterise pain processing and nutri-
tional status in patients progressing from acute to CP.
Methods
Study design
Prospective cohort study including adult patients with 
RAP, probable or definitive CP recruited from outpa-
tient clinics at the three participating sites (Hvidovre, 
Bispebjerg and Aalborg University Hospitals). The study 
is non-interventional; all participants will be treated 
and monitored according to the current best clinical 
evidence-based practice. The patient inclusion began in 
February 2019. We anticipate to complete the inclusion 
of all cohorts during a 2-year period. We will follow the 
patient cohorts for 15 years, and the anticipated comple-
tion date is 1 February 2035.
Inclusion criteria
 ► Age 18–75 years
 ► Cohort 1 (definitive CP): Patients with definitive CP 
(n=60) of any aetiology except gallstone-induced CP. 
The M-ANNHEIM diagnostic criteria will be used for 
the definition of definitive CP. Hence, patients will be 
included in this cohort if they fulfil one or more of the 
following criteria: pancreatic calcifications, moderate 
or marked pancreatic duct changes (Cambridge III or 
IV) or typical histology of CP.34
 ► Cohort 2 (suspected CP): Patients with RAP except 
gallstone-induced RAP and patients with probable CP 
according to the M-ANNHEIM criteria (n=60). RAP is 
defined as two or more cases of AP as diagnosed by the 
revised Atlanta Criteria.35 Probable CP is defined as 
patients with a typical history of CP (persistent abdom-
inal pain and/or a history of a single AP episode) in 
combination with any of the following: mild pancre-
atic duct changes (Cambridge I or II), recurrent or 
persistent pseudocysts, abnormal exocrine pancreatic 
function test or post pancreatitis diabetes mellitus 
(elevated glycated haemoglobin >3 months after diag-
nosis of pancreatitis).3 34
 ► Cohort 3 (control subjects): Subjects without any 
previous history of pancreatic or gastrointestinal 
diseases will be included in the control cohort (n=40).
Exclusion criteria
Patients with the following conditions will be excluded 
from participation in the study:
1. Pregnant or lactating patients.
2. Patients in whom MRI is contraindicated (metallic im-
plants, pacemaker, implantable cardioverter defibrilla-
tor and claustrophobia).
3. Patients with chronic liver disease, chronic renal fail-
ure, malignancy, chronic inflammatory bowel syn-
drome, chronic obstructive lung disease and pulmo-
nary fibrosis. If the patient develops any of the listed 
diseases during the study period, they will continue 
their participation in the study.
4. Patients treated with anti-inflammatory drugs of any 
kind at the time of inclusion: local or systemic cor-
ticosteroids, non-steroidal anti-inflammatory drugs 
(NSAID’s), salazopyrin or other. However, once includ-
ed, they will continue their participation even though 
they receive treatment with anti-inflammatory drugs.
sample size, time schedule and follow-up
The present study is observational. No previous long-
term prospective studies have evaluated the fibroin-
flammatory process associated with the development 
of CP and we were, therefore, unable to undertake a 
valid sample size calculation. Consequently, the sample 
size was set to 60 participants in the patient cohorts, 
assuming that 36% of participants in cohort 2 will prog-
ress to definitive CP.3 36 37 Similar sample size estimates 
apply for a recently published study protocol from 
the Consortium for the Study of Chronic Pancreatitis, 
Diabetes and Pancreatic Cancer (CPDPC) that is also 
based on MRI assessment parameters.38 We expected 
that we will be able to reach our sample size during an 
inclusion period of 2 years, based on experience from 
previous cohort studies from our departments. We antic-
ipate that all three centres will include approximately 
equal numbers of participants.
Included patients will be followed up prospectively for 15 
years. An interim analysis, assessing both clinical, functional, 
imaging and biochemical parameters will be performed 
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Table 1 Schedule of events
On inclusion Yearly Every second year
Informed consent and assessment of eligibility criteria X
Review of medical history including medication X X
Physical examination Anthropometrics X X
Vital signs X X
Clinical laboratory and biobank X X
F-elastase-1 and HbA1c X X
  Diagnostic
  imaging
Advanced MRI X X
Contrast-enhanced EUS and 
elastography
X X
Pain
processing
Quantitative sensory testing X X
Questionnaires X X
Body composition: Bioelectrical impedance X X
Muscle strength and function: Hand grip strength and timed up-and-go test X X
EUS, endoscopic ultrasound; HbA1c, glycated haemoglobin.
Table 2 Imaging assessment parameters
Method Modality Measurement variables
MRI T1, T2, MRCP Cambridge classification with modification for MRCP40
Main pancreatic duct diameter
Pancreatic dimensions and volume
DWI Apparent diffusion coefficient
DIXON Fat signal faction
EUS EUS B-mode Rosemont score12
Contrast enhanced 90 s film recorded from stomach of pancreatic body will be recorded for later 
analysis
Elastography Histogram analysis and measurement of strain ratio41
DWI, diffusion weighted imaging; EUS, endoscopic ultrasound; MRCP, MR cholangiopancreatography.
after 4 years.39 Patient cohorts will follow the same time 
schedule and plan for follow-up as outlined in table 1.
Included patients will be evaluated during a quiescent 
phase of disease; consequently, an acute attack of pancre-
atitis or exacerbation in CP requiring hospital admission 
will lead to a quarantine period of 4 weeks before evalu-
ation by the protocol can be performed. Resolution of 
pancreatitis will be documented by assessment of plasma 
amylase and C reactive protein (CRP).
On inclusion, review of medical history including medica-
tion, physical examination will be performed. The following 
patient characteristics will be recorded: age at inclusion; 
gender; date the patient was diagnosed with AP/RAP/CP; 
aetiology of pancreatitis; previous and current patterns of 
tobacco and alcohol consumption; presence of diabetes 
mellitus and other comorbidities; medications. Advanced 
MRI and contrast-enhanced EUS with elastography will be 
used to characterise pancreatic morphology40 41 (table 2). 
Endocrine and exocrine pancreatic function will be char-
acterised by HbA1c and FE and routine biochemical 
tests including white cell count, haemoglobin, platelets, 
sodium, potassium, urea, creatinine, CRP, albumin, alanine 
aminotransferase (ALT), amylase, alkaline phosphatase, 
bilirubin, INR, calcium, phosphate, magnesium, cobalamin, 
vitamin D, PTH will be obtained. In addition to routine 
biochemical tests, blood samples (see later) will be depos-
ited in a biobank for the future evaluation of biomarkers 
of inflammation, fibrosis and oxidative stress (table 3). 
Nutritional assessment and evaluation of pain processing 
by QST will be performed, and the measurement variables 
reported in table 4 will be recorded.
On subsequent yearly visits review of medical history 
including medication, patterns of smoking and alcohol 
consumption during the past year and physical examina-
tion will be performed. Endocrine and exocrine pancre-
atic function will be reassessed together with the routine 
biochemical tests outlined above. Blood samples will be 
deposited in a biobank for future evaluation of circu-
lating biomarkers and nutritional assessment and eval-
uation of pain processing by QST will be performed as 
described for the inclusion visit. In addition to the yearly 
assessments, patients will undergo advanced MRI and 
contrast-enhanced EUS as described at the inclusion visit 
every second year.
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Table 3 Circulating biomarker assessment parameters
Measurement variable
Inflammation Interelukin(IL)−4, IL-6, IL-8, IL-10, IL-12, IL-18, TNF-alpha
Fibrosis Transforming growth factor beta-1, soluble fractalkine, monocyte chemoattractant protein 1, matrix 
metalloproteinases
Oxidative stress Glutathione peroxidase, vitamin C, ferric reducing ability of plasma, malondialdehyde, 4-hydroxynonenal, 
superoxide dismutase, nitric oxide
TNF, tumour necrosis factor.
Table 4 Nutritional and QST assessment parameters
Method Measurement variable
Nutritional assessment Muscle strength: Han- held 
dynamometer
Muscle strength (kg)
Muscle function: Timed up-and-go 
test
Seconds
Body composition:
Bioelectrical impedance
Various bioelectrical impedance parameters
Assessment of pain 
processing
Pressure algometry Pressure pain and tolerance thresholds (kPa)
Temporal summation Absolute and relative change in pain scores (NRS) to 
single and repetitive pinprick stimulations
Conditioned pain modulation Absolute and relative change in pressure pain tolerance 
thresholds (kPa) before and after cold pressor test
NRS, Numerical Rating Scale; QST, quantitative sensory testing.
During the study period, patients will be counselled 
and treated according to best clinical practice, including 
advice on alcohol and smoking cessation.
biobank
Ninety millilitres of blood (processed as plasma, serum, 
buffy coat and cells) will be deposited in a biobank on the 
day of inclusion, and subsequently on a yearly basis for 15 
years. The purpose of the biobank is to allow analyses of 
potential biomarkers for disease progression. The analyses 
will be conducted before 1 January 2040 (the study termi-
nation date). Any remaining blood will be destroyed. The 
deposited blood material will also enable us to perform 
genetic studies if deemed relevant. The genetic anal-
yses will only be performed following approval from the 
Regional Committee on Health Research Ethic.
patient and public involvement
Patients and public were not involved in the design and 
recruitment of the present study. As the study is designed 
as a part of a clinical setup and monitoring, the results of 
the study will be continuously discussed with the partici-
pating patients.
study procedures
MRI
MRI is performed in collaboration with the radiological 
departments of the participating institutions. A common 
MRI protocol is used at all participating sites; the protocol 
has been described in detail previously.8 42
Endoscopic ultrasound
EUS is performed under conscious sedation with fasting 
(min 6 hours) patient lying on the left side, and under 
continuous monitoring of pulse, blood pressure and 
oxygenation. EUS B-mode is applied to calculate Rose-
mont score (performed before further examination). 
Ten seconds sequences from the body and head of the 
pancreas are recorded. From stomach, elastography is 
applied on pancreatic body: 10 s loop will be recorded 
with three images and a histogram. Contrast-enhanced 
EUS is performed by a bolus administration of 2.4 mL 
SonoVue. A film sequence of 90 s is recorded.
Circulating biomarkers
Venous blood samples are drawn from an antecubital 
vein. Following this procedure, the blood is processed as 
plasma, serum, buffy coat and cells, and stored at −80°C 
until subsequent analysis (biobank).
Quantitative sensory testing
Pressure algometry
The pressure pain detection threshold (pPDT) and pres-
sure pain tolerance threshold (pPTT) are determined 
on six different sites, corresponding to the somatic 
dermatomes above the clavicle (C5), middle of the ante-
rior axillary fold (T4), dorsum (T10(D)), spina illiaca 
anterior superior (L1), rectus femoris (L4) and the 
abdominal pancreatic area (T10(P)). Pressure algom-
etry is performed using an electronic pressure algometer 
(Somedic AB, Stockholm, Sweden), with a surface area of 
1 cm2. Pressure is increased at a rate of 30 kPa/sec until  on S
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pPDT and pPTT is reached, and subjects are instructed to 
press a button at this point, which stops the stimulation, 
and the corresponding pressure (kPa) is recorded.
Conditioned pain modulation
To induce conditioned pain modulation (CPM), a cold 
pressor test is applied as the conditioning stimulus and 
pressure stimulations are used as test stimuli. Pressure 
stimulation is applied at the on the non-dominant rectus 
femoris until subjects reach the PTT using the equipment 
and procedure described above. The cold pressor test is 
performed by asking the subject to immerse their domi-
nant hand in cooled water (2°C) for 2 min, or less if the 
evoked pain is considered to be intolerable. The CPM 
effect is assessed as the absolute and relative change in 
PTT before and after the cold pressor test.
Temporal summation
In this test, the perceived intensity of a single pinprick 
stimulus of 256 mN, is tested over the epigastric area 
(T10) and the dominant forearm and compared with that 
of a series of 10 repetitive pinprick stimuli of the same 
physical intensity (1/s applied within an area of 1 cm2). 
The subject is asked to give a pain rating representing the 
single stimulus, and the estimated mean over the whole 
series of 10 stimuli using a ‘0–10’ Numerical Rating Scale 
(NRS). The temporal summation ratio is calculated as the 
absolute and relative change in pain scores to single and 
repetitive pinprick stimulations. Pin pricks are applied 
using a modified von Frey hairs (Optihair2-Set, Marstock 
Nervtest, Germany).
nutritional assessment
Body composition
Bioelectrical impedance analysis enables a fast and 
accurate measurement of body compartments. For the 
purpose of this study, bioelectrical impedance will be 
assessed by the seca medical Body Composition Analyzer 
514/515 (Seca, Hamburg) or BioScan 920-II (Maltron, 
Essex, UK). The analyser consists of a platform with an 
integrated scale, a handrail system and a display and oper-
ation unit. The device uses four pairs of electrodes that 
are positioned at each hand and foot, with one electrode 
in each pair through which the electrical current enters 
the limb and the other electrode detects the voltage drop. 
Analysis time is 20–30 s.
Hand grip strength
Muscle strength is determined by HGS measured to the 
nearest kilogram using a hydraulic hand dynamometer 
(NC70142, North Coast Medical, Arcata, California, USA 
or Jamar Smart Hand Dynamometer, Patterson medical, 
Warrenville, Illinois, USA). The dynamometer is held in 
the second handle position and the patient is instructed to 
sit on a chair with the shoulder neutrally rotated, holding 
the elbow bend 90° and the wrist in neutral position. HGS 
is measured three times for each hand; assessments are 
separated by intervals of approximately 10 s. The highest 
value for each hand is recorded and the mean value is 
calculated.
Timed up-and-go test
Muscle function is characterised by the TUG. This test is 
performed and reported (seconds) as the time it takes a 
patient to get up from sitting position on a chair, walk 3 
m, turn around, walk back to the chair and sit down.
Questionnaires
Quality of life
The European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORCT 
QLQ-C30) is used to document life quality, physical 
function and a number of other health-related parame-
ters.43 The questionnaire has been validated specifically 
for assessment of patients with CP and is composed of 
single-item measures and multi-item scales with scores 
ranging from 0 to 100 after linear transformation of the 
raw score.44 A high score for a functional scale represents 
a high level of functioning, as does a high score for the 
global health status, while a high score for the symptom 
items represents a high level of symptomatology.
Pain symptoms
The brief pain inventory short form is used to document 
the patients pain symptoms and its interference with daily 
activities (interference score).45
EthICs And dIssEMInAtIon
This study will be conducted according to the Danish 
national legislation on health. The project will lead to 
better understanding of fibrogenic process that leads to 
CP and better understanding of changes in pain percep-
tion and nutritional aspects during the course of the 
disease. The combination of diagnostic imaging and 
biochemical parameters will enable improved identifica-
tion of those patients who are at particular risk of devel-
oping early CP. The improvement in identification is vital, 
as there are emerging inhibitors of fibrosis, which poten-
tially could impair the ongoing fibrogenesis of pancreas. 
Hence, the project will lead to new strategies for patient 
management. Socioeconomically, the results of this study 
may lead to reduced costs for hospitalisations and acci-
dents related to CP. The techniques developed in the 
project period may also be used to understand and eval-
uate the fibrogenic processes in other organs, primarily 
the liver.
The investigations and examinations that are planned 
in present protocol are all a part of existing routine 
workup. The major change associated with the participa-
tion in the study is that the examinations are scheduled at 
regular time intervals. Blood for the purpose of biobank 
will be drawn simultaneously with the routine blood tests. 
FE, bioelectrical impedance, hand grip test, TUG test, 
QST and MRI are not associated with any risks. The EUS 
can be associated with discomfort and in very rare cases 
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with serious complications such as perforation of oesoph-
agus, stomach or duodenum.
The study may contain several combinations of data that 
may be written as papers in peer-reviewed international 
journals. We will publish the study results regardless of 
whether the results are positive, negative or inconclusive.
dIsCussIon
Recently the US-based consortium for the Study of CPDPC 
has published their study protocol for the Prospective 
Evaluation of Chronic Pancreatitis for Epidemiologic 
and Translational Studies (PROCEED).39 Although the 
PROCEED study is mainly based on CT-based imaging 
parameters, as opposed to the MRI-based approach in 
our study, the design of the PROCEED study is in many 
ways comparable to ours. Hence, both studies focus on 
prospective assessment of disease progression parameters 
in well-defined cohorts of patients with CP at different 
disease stages using cross-sectional imaging and circu-
lating biomarkers. The patient cohorts have been char-
acterised using comparatively similar criteria, which will 
allow comparison across studies.
A unique characteristic of our study, compared with 
the PROCEED study, is the annual assessment of pain 
processing and modulation based on a QST protocol 
specifically designed for pancreatic pain. In addition, 
detailed nutritional assessment, using bioelectrical imped-
ance and muscle function tests, distinct our protocol from 
that of the PROCEED study.39 Finally, our study popula-
tion comprises of a very homogeneous population, both 
genetically, socially and economically, which provides us 
with an opportunity to study the natural course of CP with 
reduced bias from diverse patient characteristics.
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